FDA US Agent: What Happens When They Go Silent — and You Picked Them on Price

There's one decision that comes up again and again in US market entry projects: treating the choice of US Agent like a quote comparison.

"It's just an address on a form — might as well go with whoever's cheapest."

From a working-level perspective, that's a perfectly reasonable call. The problem is the assumption behind it.

If a US Agent's job really were nothing more than renting out an address, that would be the right choice. But look at the actual responsibilities FDA regulations assign to this role, and the picture changes.

The US Agent's Real Job Isn't Renting an Address — It's Being the Emergency Line

The US Agent system is often mistaken for a paperwork formality, but FDA regulations define the role's actual duty as receiving and responding to FDA's urgent communications in real time. FDA doesn't call Korean manufacturers directly, and it doesn't send friendly notices in Korean. Instead of reaching out to a head office sitting on the other side of the clock, FDA routes every urgent document request and every surprise inspection notice through the US Agent registered on American soil.

In other words, the US Agent is the only communication line between FDA and the Korean manufacturer. If that line goes dead, the problem is already unfolding — and headquarters won't even know it yet.

What Actually Happens When Nobody Responds

From here, the consequences diverge depending on the product category.

-Dietary Supplements (Classified as Food)

Under FSMA (the Food Safety Modernization Act), if FDA requests an inspection and gets no response within 24 hours, that silence alone counts as a refusal. The consequence is placement on Import Alert 99-32 — the industry's red list. Once listed, every product from that facility is automatically detained without physical examination (DWPE), and getting off the list means requesting and passing a new inspection. Industry estimates put that process at a year or more.

-Medical Devices

Devices fall under a different statute. Under Section 501(j) of FDASIA and FDARA, delaying, limiting, or refusing an inspection means the device itself is deemed "adulterated." There's no fixed 24-hour clock the way there is for food, but the outcome isn't much different — it can start with a warning letter and escalate to holds on new clearance reviews, effectively pushing the company out of the US market.

Both paths start the same way: FDA reached out, and there was no one there to receive it.

It Looks Even Worse From the US Buyer's Side

To the manufacturer, this might look like "one missed inspection." To the US importer or buyer already distributing that product, it's inventory stuck in a warehouse, broken delivery timelines, and a partner's trust on the line. The moment customs holds a shipment, responsibility for the resulting losses ends up back with the Korean manufacturer. One poorly chosen agent, and the US distribution channel it took years to build can collapse.

What This Job Actually Requires Isn't Speed — It's Judgment

When people talk about US Agent risk, they usually assume the failure mode is someone not reading an email. In practice, the harder problem runs the other way: the email gets read, but what it's actually asking for gets misjudged — and that's what lets a small issue grow into a big one.

A few examples:

• Not all FDA correspondence carries the same weight. 

A scheduling notice, a 483 observation issued after an inspection, and a Warning Letter each demand a different response speed and a different approach. Treat every message the same way, and you'll miss the urgent one while overreacting to the routine one.

• Even rescheduling has a "reasonable cause" standard. 

Postponing an inspection isn't impossible in itself. FDA guidance states that a schedule change backed by a reasonable cause isn't treated as a refusal. The real question is what qualifies as reasonable. Drawing that line correctly is the agent's actual job.

• The same holds for Additional Information (AI) requests during 510(k) review. 

Interpret the request correctly and you send exactly what's needed. Read it too broadly and you bury the reviewer in unnecessary material, which only slows things down. Read it too narrowly and you miss the point, triggering another round of AI. Getting that balance right isn't something you learn from the regulation text — it comes from knowing how FDA reviewers actually work.

In short, the expertise a US Agent needs isn't "forwarding messages quickly." It's judging, in real time, what a piece of correspondence is actually demanding and how much room there is to negotiate. That's a different skill set entirely from response speed or English fluency.

What Provision Does Isn't Renting an Address — It's Crisis Response

FDA regulation is a living thing. With cybersecurity requirements tightening for medical devices and supply chain scrutiny intensifying for dietary supplements, FDA's enforcement posture is sharper than it's ever been. Choosing an unvetted agent purely because it's cheap means putting your company's most valuable asset — its access to the US market — on the table.

Provision's team of regulatory specialists, including former FDA staff, moves the moment an inspection notice or urgent query lands, reviewing documentation and building a response plan immediately rather than after the fact.

In a regulatory area where a company's survival is on the line, comparing quotes on price alone is the riskiest choice you can make. Now is a good time to check whether your safety net in the US actually holds.

For inquiries or expert assistance, please contact us today.

>>>>> Start Your Consultation

CONTACT US

Office: 1-909-493-3276

Email: ask@provisionfda.com